Corrigendum to “Inhibition of p38 and ERK1/2 pathways by Sparstolonin B suppresses inflammation-induced melanoma metastasis” [Biomed. Pharmacother. 98 (2018) 382–389]

Corrigendum to “Inhibition of p38 and ERK1/2 pathways by Sparstolonin B suppresses inflammation-induced melanoma metastasis” [Biomed. Pharmacother. 98 (2018) 382–389]

Bibliographic Details
Main Authors:	Ya-Min Tang, Qing-Yun Cao, Xing-Yu Guo, Shui-Hua Dong, Jin-Ao Duan, Qi-Nan Wu, Qiao-Li Liang
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Series:	Biomedicine & Pharmacotherapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332223014142

Similar Items

‘Corrigendum to “Resveratrol inhibits proliferation, migration and invasion via Akt and ERK1/2 signaling pathways in renal carcinoma cells” [Biomed. Pharmacother. 98 (2018) 36–44]’
by: Yuwan Zhao, et al.
Published: (2022-09-01)

Corrigendum to “Valproate, divalproex, valpromide: Are the differences in indications justified?” [Biomed. Pharmacother., 158 (2023) 114051]
by: Clément Delage, et al.
Published: (2023-12-01)

Corrigendum to “Effects of oligonol on the submandibular gland in ovariectomized rats” [Biomed. Pharmacother. 141 (2021) 111897]
by: Jeong Hun Kim, et al.
Published: (2023-09-01)

Corrigendum to “Steatosis in metabolic diseases: A focus on lipolysis and lipophagy” [Biomed. Pharmacother. 160 (2023) 114311]
by: Xingtao Zhao, et al.
Published: (2023-07-01)

Corrigendum to “Insights into the implementation of Fibronectin 1 in the cartilage tissue engineering” [Biomed. Pharmacother. 148 (2022) 112782]
by: Murad Alahdal, et al.
Published: (2022-09-01)

Corrigendum to “Tegaserod maleate exhibits antileukemic activity by targeting TRPM8” [Biomed. Pharmacother. 154 (2022) 113566]
by: Xiaoling Xie, et al.
Published: (2023-10-01)

Retraction notice to 'Potential role of andrographolide in the proliferation of osteoblasts mediated by the ERK signaling pathway' [Biomed. Pharmacother. 83 (2016) 1335–1344]
by: Bo Li, et al.
Published: (2023-07-01)

Corrigendum to “Neopetroside-B alleviates doxorubicin-induced cardiotoxicity via mitochondrial protection” [Biomed. Pharmacother. 165 (2023) 115232]
by: Chang Shin Yoon, et al.
Published: (2023-12-01)

Corrigendum to “Qing Chang Hua Shi granule ameliorate inflammation in experimental rats and cell model of ulcerative colitis through MEK/ERK signaling pathway” [Biomed. Pharmacother. 116 (2019) 108967]
by: Lei Zhu, et al.
Published: (2023-07-01)

Corrigendum to “The gut microbes in inflammatory bowel disease: Future novel target option for pharmacotherapy” Biomed. Pharmacother. 165 (2023) 114893
by: Shuo Yuan, et al.
Published: (2024-02-01)

Corrigendum to “The potential molecular pathways of astragaloside-IV in colorectal cancer: A systematic review” [Biomed. Pharmacother. 167 (2023) 115625]
by: Tang Ziyang, et al.
Published: (2023-12-01)

Retraction notice to “MicroRNA-613 impedes the proliferation and invasion of glioma cells by targeting cyclin-dependent kinase 14” [Biomed. Pharmacother. 98 (2018) 636–642]
by: Qi Li, et al.
Published: (2024-04-01)

Retraction notice to “Stress induced phosphoprotein 1 promotes tumor growth and metastasis of melanoma via modulating JAK2/STAT3 pathway” [Biomed. Pharmacother. 116 (2019) 108962]
by: Xiaoyan Sun, et al.
Published: (2023-04-01)

Corrigendum to “Emerging strategy for the treatment of urothelial carcinoma: Advances in antibody-drug conjugates combination therapy” Biomed. Pharmacother. 171 (2024) 116152
by: Xiangyun You, et al.
Published: (2024-04-01)

Corrigendum to “Sacubitril/valsartan combination enhanced cardiac glycophagy and prevented the progression of murine diabetic cardiomyopathy” [Biomed. Pharmacother. 153 (2022) 113382]
by: Dina Salem Abdelaziz Elshenawy, et al.
Published: (2022-12-01)

Retraction notice to “Corrigendum to 'mPEG-b-P(Glu-co-Phe) nanoparticles increase gastric retention time and gastric ulcer treatment efficacy of 20(S)-ginsenoside Rg3' [Biomed. Pharmacother. 146 (2022) 112608]” [Biomed. Pharmacother. 152 (2022) 113213]
by: Lanqing Cao, et al.
Published: (2023-04-01)

Corrigendum to “Ferroptosis: A new view on the prevention and treatment of diabetic kidney disease with traditional Chinese medicine” Biomed. Pharmacother. 170 (2024) 115952
by: Yu Chen, et al.
Published: (2024-01-01)

Corrigendum to “Antidiabetic and antioxidant activities of Mitragyna speciosa (kratom) leaf extract in type 2 diabetic rats” [Biomed. Pharmacother. 162 (2023) 114689]
by: Pengpeng Zhang, et al.
Published: (2023-08-01)

Corrigendum to “vanillic acid attenuates effects of transient bilateral common carotid occlusion and reperfusion in rats” [Biomed. Pharmacother. 96 (2017) 667–674]
by: Seyed Esmaeil Khoshnam, et al.
Published: (2023-09-01)

Corrigendum to: “Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis”, [Biomed. Pharmacother., 161; (2023): 114472]
by: Liang Shan, et al.
Published: (2023-06-01)

Corrigendum to “CRKL knockdown promotes in vitro proliferation, migration and invasion, in vivo tumor malignancy and lymph node metastasis of murine hepatocarcinoma Hca-P cells” [Biomed. Pharmacother. 71 (2015) 84–90]
by: Ji Shi, et al.
Published: (2023-12-01)

Corrigendum to “MicroRNA-876-5p inhibits epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by targeting BCL6 corepressor like 1” [Biomed. Pharmacother. 103 (2018) 645–652]
by: Qiuran Xu, et al.
Published: (2023-07-01)

Corrigendum to: “Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death” [Biomed. Pharmacother. 153 (2022) 113511]
by: Li Liu, et al.
Published: (2023-12-01)

Corrigendum to “In vitro and in vivo antidiabetic activity, isolation of flavonoids, and in silico molecular docking of stem extract of Merremia tridentata (L.)” [Biomed. Pharmacother. (2022) 112611]
by: Lenh Vo Van, et al.
Published: (2023-11-01)

Corrigendum to “Aloe vera gel improves behavioral deficits and oxidative status in streptozotocin-induced diabetic rats” [Biomed. Pharmacother. 96 (2017) 279–290]
by: Seyed Reza Fatemi Tabatabaei, et al.
Published: (2023-09-01)

Corrigendum to “Oviductus ranae protein hydrolysate (ORPH) inhibits the growth, metastasis and glycolysis of HCC by targeting miR-491-5p/PKM2 axis” [Biomed. Pharmacother. 107 (2018) 1692–1704]
by: Qiuran Xu, et al.
Published: (2023-01-01)

Refuge (38.2) 2022 - General Issue (print copy)
by: Refuge
Published: (2023-02-01)

Corrigendum to “Discussing pathologic mechanisms of Diabetic retinopathy & therapeutic potentials of curcumin and β-glucogallin in the management of Diabetic retinopathy” Biomed. Pharmacother. 169 (2023) 115881
by: Manni Rohilla, et al.
Published: (2024-01-01)

Corrigendum to “Protective effects of Punica granatum (pomegranate) peel extract on concanavalin A-induced autoimmune hepatitis in mice” [Biomed. Pharmacother. 100 (2018) 213–220]
by: Tingting Wang, et al.
Published: (2023-12-01)

Corrigendum to “New insights about the PDGF/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies” [Biomed. Pharmacother. 161 (2023) 114491]
by: Pratibha Pandey, et al.
Published: (2023-11-01)

Corrigendum to “Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies” [Biomed. Pharmacother. 150 (2022) 112949]
by: Li-ping Zhao, et al.
Published: (2023-08-01)

Corrigendum to “A nuclear targeted Dox-aptamer loaded liposome delivery platform for the circumvention of drug resistance in breast cancer” [Biomed. Pharmacother. 117 (2019) 109072]
by: Xin Li, et al.
Published: (2023-09-01)

Corrigendum to ‘dyslipidemia induced inflammatory status, platelet activation and endothelial dysfunction in rabbits: Protective role of 10-dehydrogingerdione’ [Biomed. Pharmacother. (2019) pp. 456–464]
by: Mohamed Mahmoud El-Seweidy, et al.
Published: (2023-05-01)

Corrigendum to ‘Jinlong Capsule (JLC) inhibits proliferation and induces apoptosis in human gastric cancer cells in vivo and in vitro’ Biomed. Pharmacother. 107 (2018) 738–745
by: Dan Li, et al.
Published: (2023-10-01)

Corrigendum to: “Gegen Qinlian decoction ameliorates murine colitis by inhibiting the expansion of Enterobacteriaceae through activating PPAR-γ signaling” Biomed. Pharmacother. 154 (2022) 113571
by: Jingyi Hu, et al.
Published: (2023-01-01)

Corrigendum to “Schisandrin A inhibits triple negative breast cancer cells by regulating Wnt/ER stress signaling pathway” [Biomed. Pharmacother. 115 (2019) 108922]
by: Xiaohong Xu, et al.
Published: (2022-05-01)

Retraction Notice to “Pharmacological evaluation of continentalic acid for antidiabetic potential” [Biomed. Pharmacother. 138 (2021) 111411]
by: Iqra Liaquat, et al.
Published: (2024-01-01)

Corrigendum to “Notoginsenoside R1 activates the NAMPT-NAD+-SIRT1 cascade to promote postischemic angiogenesis by modulating Notch signaling” [Biomed. Pharmacother. 140 (2021) 111693]
by: Ting Zhu, et al.
Published: (2023-09-01)

Corrigendum to: “Mitoquinone ameliorated airway inflammation by stabilizing β-catenin destruction complex in a steroid-insensitive asthma model” [Biomed. Pharmacother. vol. 162 (2023) 114680]
by: Junwen Huang, et al.
Published: (2023-09-01)

Corrigendum to “Betaine prevents and reverses the behavioral deficits and synaptic dysfunction induced by repeated ketamine exposure in mice” by Shao-Tsu Chen [Biomed. Pharmacother. 144 (2021) 112369]
by: Shao-Tsu Chen, et al.
Published: (2023-07-01)